## Kees van Gool

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3077480/publications.pdf

Version: 2024-02-01

57	812	16	26
papers	citations	h-index	g-index
57	57	57	1128
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Paying for value: options for value-based payment reform in Australia. Australian Health Review, 2022, 46, 129-133.	1.1	7
2	Health care cost of crusted scabies in Aboriginal communities in the Northern Territory, Australia. PLoS Neglected Tropical Diseases, 2022, 16, e0010288.	3.0	1
3	Evaluation of the Victorian Healthy Homes Program: protocol for a randomised controlled trial. BMJ Open, 2022, 12, e053828.	1.9	O
4	Improving outcomes for marginalised rural families through a care navigator program. Health Promotion Journal of Australia, 2021, 32, 285-294.	1.2	1
5	Does more investment in primary care improve health system performance?. Health Policy, 2021, 125, 717-724.	3.0	4
6	Differences in health care spending and utilization among older frail adults in <scp>highâ€income</scp> countries: <scp>ICCONIC</scp> hip fracture persona. Health Services Research, 2021, 56, 1335-1346.	2.0	22
7	Within and across country variations in treatment of patients with heart failure and diabetes. Health Services Research, 2021, 56, 1358-1369.	2.0	5
8	International comparison of health spending and utilization among people with complex multimorbidity. Health Services Research, 2021, 56, 1317-1334.	2.0	24
9	Differences in health outcomes for h ighâ€need h ighâ€cost patients across h ighâ€income countries. Health Services Research, 2021, 56 Suppl 3, 1347-1357.	2.0	13
10	1437Rates of low value care in NSW public hospitals: variation between public and private inpatients. International Journal of Epidemiology, 2021, 50, .	1.9	0
11	International comparison of spending and utilization at the end of life for hip fracture patients. Health Services Research, 2021, 56, 1370-1382.	2.0	9
12	Health care use in response to health shocks: Does socioâ€economic status matter?. Health Economics (United Kingdom), 2021, 30, 3032-3050.	1.7	2
13	How much of Australia's health expenditure is allocated to general practice and primary healthcare?. Australian Journal of General Practice, 2021, 50, 673-678.	0.8	6
14	A methodology for identifying highâ€need, highâ€cost patient personas for international comparisons. Health Services Research, 2021, 56, 1302-1316.	2.0	5
15	Rates of Low-Value Service in Australian Public Hospitals and the Association With Patient Insurance Status. JAMA Network Open, 2021, 4, e2138543.	5.9	4
16	Measuring horizontal inequity in healthcare utilisation: a review of methodological developments and debates. European Journal of Health Economics, 2020, 21, 171-180.	2.8	28
17	Accommodation payment plans in residential aged care: The impact of consumer choice. Australasian Journal on Ageing, 2020, 39, e103-e109.	0.9	3
18	Inequity in healthcare use among the indigenous population living in non-remote areas of Australia. Public Health, 2020, 186, 35-43.	2.9	7

#	Article	IF	Citations
19	Horizontal inequity in the utilisation of healthcare services in Australia. Health Policy, 2020, 124, 1263-1271.	3.0	20
20	Private finance publicly subsidized: the case of Australian health insurance., 2020,, 41-64.		3
21	Inequity in physician visits: the case of the unregulated fee market in Australia. Social Science and Medicine, 2020, 255, 113004.	3.8	16
22	Failure to access prescribed pharmaceuticals by older patients with chronic conditions. Australian Health Review, 2020, 44, 270.	1.1	0
23	Physician pricing behavior: Evidence from an Australian experiment. Journal of Economic Behavior and Organization, 2019, 161, 20-34.	2.0	8
24	A systematic review of scabies transmission models and data to evaluate the cost-effectiveness of scabies interventions. PLoS Neglected Tropical Diseases, 2019, 13, e0007182.	3.0	19
25	The business of integrated care: implementing new models of care in a fee-for-service setting. Journal of Integrated Care, 2018, 26, 16-28.	0.5	7
26	Is low-priced primary care bad for quality? Evidence from Australian general practice. Applied Economics, 2018, 50, 475-491.	2.2	4
27	Supplier-induced demand for urgent after-hours primary care services. Health Economics (United) Tj ETQq $1\ 1\ 0$ .	784314 rg	gBT /Overlock
28	The prevalence of persistence and related health status: An analysis of persistently high healthcare costs in the short term and medium term. Social Science and Medicine, 2018, 211, 147-156.	3.8	4
29	How common is multiple general practice attendance in Australia?. , 2018, 47, 289-296.		18
30	Bleeding Hearts, Profiteers, or Both: Specialist Physician Fees in an Unregulated Market. Health Economics (United Kingdom), 2017, 26, 528-535.	1.7	32
31	Role of Cost on Failure to Access Prescribed Pharmaceuticals: The Case of Statins. Applied Health Economics and Health Policy, 2017, 15, 625-634.	2.1	8
32	The Rise and Fall in Out-of-Pocket Costs in Australia: An Analysis of the Strengthening Medicare Reforms. Health Economics (United Kingdom), 2017, 26, 962-979.	1.7	14
33	Evaluating the Impact of Hospital Based Drug and Alcohol Consultation Liaison Services. Journal of Substance Abuse Treatment, 2016, 68, 36-45.	2.8	13
34	The hidden costs of drug and alcohol use in hospital emergency departments. Drug and Alcohol Review, 2016, 35, 359-366.	2.1	21
35	Appropriateness of Prescriptions of Recommended Treatments in Organisation for Economic Co-operation and Development Health Systems: Findings Based on the Long-Term Registry of the European Society of Cardiology on Heart Failure. Value in Health, 2015, 18, 1098-1104.	0.3	11
36	Cost of care for cystic fibrosis: an investigation of cost determinants using national registry data. European Journal of Health Economics, 2015, 16, 709-717.	2.8	17

#	Article	IF	CITATIONS
37	Towards actionable international comparisons of health system performance: expert revision of the OECD framework and quality indicators. International Journal for Quality in Health Care, 2015, 27, 137-46.	1.8	115
38	Cost of cancer care for patients undergoing chemotherapy: The <scp>E</scp> lements of <scp>C</scp> ancer <scp>C</scp> are study. Asia-Pacific Journal of Clinical Oncology, 2015, 11, 178-186.	1.1	13
39	Can administrative data be used to measure chemotherapy side effects?. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 215-222.	1.4	3
40	Delays in access to affordable medicines: putting policy into perspective – authors' response. Australian Health Review, 2014, 38, 16.	1.1	0
41	Understanding the Costs of Care for Cystic Fibrosis: An Analysis by Age and Health State. Value in Health, 2013, 16, 345-355.	0.3	71
42	SURGEONS' VIEWS OF HEALTH TECHNOLOGY ASSESSMENT IN AUSTRALIA: ONLINE PILOT SURVEY. International Journal of Technology Assessment in Health Care, 2013, 29, 309-314.	0.5	2
43	Modelling the Relationship between Child Abuse and Longâ€Term Health Care Costs and Wellbeing: Results from an Australian Communityâ€Based Survey. Economic Record, 2013, 89, 300-318.	0.4	8
44	Delays in access to affordable medicines: putting policy into perspective. Australian Health Review, 2012, 36, 412.	1.1	29
45	Cost-effectiveness of carrier screening for cystic fibrosis in Australia. Journal of Cystic Fibrosis, 2012, 11, 281-287.	0.7	22
46	Chemotherapy Administration. Pharmacoeconomics, 2012, 30, 1173-1186.	3.3	3
47	Nursing Takes Time: Workload Associated With Administering Cancer Protocols. Clinical Journal of Oncology Nursing, 2010, 14, 735-741.	0.6	16
48	Who's Getting Caught? An Analysis of the Australian Medicare Safety Net. Australian Economic Review, 2009, 42, 143-154.	0.7	32
49	Resource allocation and health technology assessment in Australia: Views from the local level. International Journal of Technology Assessment in Health Care, 2009, 25, 134-140.	0.5	15
50	The Distribution of Household Health Expenditures in Australia*. Economic Record, 2008, 84, S99.	0.4	16
51	Economic evaluation of cystic fibrosis screening: A review of the literature. Health Policy, 2008, 85, 133-147.	3.0	27
52	Decision makers' perceptions of health technology decision making and priority setting at the institutional level. Australian Health Review, 2008, 32, 520.	1.1	27
53	Targeting services to reduce social inequalities in utilisation: an analysis of breast cancer screening in New South Wales. Australia and New Zealand Health Policy, 2007, 4, 12.	2.2	10
54	Economic Evidence at the Local Level. Pharmacoeconomics, 2007, 25, 1055-1062.	3.3	15

## KEES VAN GOOL

#	Article	IF	CITATIONS
55	Letters to the Editor: Can we deny patients expensive drugs?. Australian Prescriber, 2007, 30, 59-63.	1.0	0
56	Diagnosis and prognosis of Australia&s health information for evidence-based policy. Journal of Health Services Research and Policy, 2002, 7, 40-45.	1.7	2
57	Adapting portfolio theory for the evaluation of multiple investments in health with a multiplicative extension for treatment synergies. European Journal of Health Economics, 2002, 3, 47-53.	2.8	24